Study Demonstrates Value of Neuro Oncology Software

A new study published in Neurosurgery Open illustrates the clinical impact of Imaging Biometrics’ (IB) neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors.

The ongoing challenge in treating brain tumors is that new or recurrent tumor can appear the same as treatment effect on traditional postcontrast MR images. Today’s standard of care requires either many weeks of follow-up imaging or an invasive surgical biopsy to confirm diagnosis. IB, a subsidiary of IQ-AI Limited, has developed and validated a non-invasive, timely and quantitative imaging solution that addresses this issue.

For the published study, IB Clinic, IB’s non-invasive, neuro-oncology platform, was used to distinguish brain tumor tissue from treatment effect. The results explained the discordance between the intraoperative assessment and the pathologic diagnosis, suggesting that IB Clinic should be routinely used to optimize surgical guidance and pathologic diagnosis, which in turn would lead to optimized treatment management and patient outcomes.

“We are relying on fractional tumor burden (FTB) maps more routinely in our clinical practice, as well as our weekly comprehensive multidiscipline brain tumor boards. They have proven to provide information that can help interpret MR findings and optimize treatment for our patients,” said Dr. Jennifer Connelly, MD, Associate Professor of Neurology and Co-Director of the Neuro-oncology Program at Froedtert and the Medical College of Wisconsin and lead author of the paper.

The case report authors are clinicians and scientists from the Medical College of Wisconsin, which is affiliated with Froedtert Health. For more than a decade, Froedtert Health’s radiology department has used IB software for analyzing MR datasets within the OsiriX (Mac based) environment, which requires manual user intervention. Froedtert Health has recently acquired the upgraded IB Clinic – Container edition, which automatically generates quantitative rCBV and Delta T1 maps. This platform-independent processing application networks with scanners and PACS and requires no manual intervention.

“There is growing interest in our automated platform,” said Michael Schmainda, CEO of IB. “The seamless integration in clinical workflows, coupled with IB’s quantitative and validated output, is gaining attention from large and small hospitals alike.”

IQ-AI has sold multiple licenses of its IB software to clients such as Eastern Alabama Medical Center, Vanderbilt University Medical Center, Virginia Polytechnic Institute, Rhode Island Hospital, and others.